Abstract
The Rrm2b gene encodes p53R2, a catalytic subunit of ribonucleotide reductase that is required for DNA repair. Embryonic stem (ES) cells containing a retroviral insertion in the Rrm2b locus were used to generate mutant mice. Analysis of kidney RNA from Rrm2b (−/−) mice showed that the retroviral insertion disrupted expression of Rrm2b transcripts. Rrm2b (−/−) pups were represented at the expected Mendelian ratios at 10–12 days of age and grew normally past weaning. Mice failed to thrive after 6 weeks of age and began to die by 8 weeks of age. Phenotyping revealed that Rrm2b (−/−) mice died from a severe glomerular lesion that led to nephrotic syndrome and chronic renal failure. In kidneys of Rrm2b (−/−) mice, podocytes were enlarged and there was evidence of foot process effacement by 6 weeks of age. By 8 weeks of age, progressive podocyte hypertrophy and loss of foot processes was accompanied by hypertrophy of glomerular capillary endothelial cells that was extensive enough to restrict capillary blood flow. Collapsing glomerulopathy with avascular glomeruli was widespread in mice surviving beyond 9 weeks of age. Additional abnormalities in other organ systems were minor or consistent with secondary effects of renal failure. These findings suggest that lack of p53R2, the protein encoded by Rrm2b, has early and relatively selective detrimental effects on the kidney glomerulus that lead to rapid death from progressive renal failure.
Similar content being viewed by others
References
Zambrowicz BP, Turner CA, Sands AT (2003) Predicting drug efficacy: knockouts model pipeline drugs of the pharmaceutical industry. Curr Opin Pharmacol 3:563–570
Zambrowicz BP, Sands AT (2003) Knockouts model the 100 best-selling drugs—will they model the next 100? Nat Rev Drug Discov 2:38–51
Zambrowicz BP, Friedrich GA, Buxton EC, Lilleberg SL, Person C, Sands AT (1998) Disruption and sequence identification of 2,000 genes in mouse embryonic stem cells. Nature 392:608–611
Walke DW, Han C, Shaw J, Wann E, Zambrowicz B, Sands A (2001) In vivo drug target discovery: identifying the best targets from the genome. Curr Opin Biotechnol 12:626–631
BeltrandelRio H, Kern F, Lanthorn T, Oravecz T, Piggott J, Powell D, Ramirez-Solis R, Sands AT, Zambrowicz B (in press) In: Carroll P (ed) Model organisms in drug discovery. Wiley & Sons, Chichester, UK
Abuin A, Holt KH, Platt KA, Sands AT, Zambrowicz BP (2002) Full-speed mammalian genetics: in vivo target validation in the drug discovery process. Trends Biotechnol 20:36–42
Wattler S, Kelly M, Nehls M (1999) Construction of gene targeting vectors from lambda KOS genomic libraries. Biotechniques 26:1150–1156, 1158, 1160
Zambrowicz BP, Abuin A, Ramirez-Solis R, Richter LJ, Piggott J, BeltrandelRio H, Buxton EC, Edwards J, Finch RA, Friddle CJ, Gupta A, Hansen G, Hu Y, Huang W, Jaing C, Key BW Jr, Kipp P, Kohlhauff B, Ma ZQ, Markesich D, Payne R, Potter DG, Qian N, Shaw J, Schrick J, Shi ZZ, Sparks MJ, Van Sligtenhorst I, Vogel P, Walke W, Xu N, Zhu Q, Person C, Sands AT (2003) Wnk1 kinase deficiency lowers blood pressure in mice: a gene-trap screen to identify potential targets for therapeutic intervention. Proc Natl Acad Sci USA 100:14109–14114
Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, Takei Y, Nakamura Y (2000) A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404:42–49
Guittet O, Hakansson P, Voevodskaya N, Fridd S, Graslund A, Arakawa H, Nakamura Y, Thelander L (2001) Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells. J Biol Chem 276:40647–40651
Kimura T, Takeda S, Sagiya Y, Gotoh M, Nakamura Y, Arakawa H (2003) Impaired function of p53R2 in Rrm2b-null mice causes severe renal failure through attenuation of dNTP pools. Nat Genet 34:440–445
Donoviel DB, Freed DD, Vogel H, Potter DG, Hawkins E, Barrish JP, Mathur BN, Turner CA, Geske R, Montgomery CA, Starbuck M, Brandt M, Gupta A, Ramirez-Solis R, Zambrowicz BP, Powell DR (2001) Proteinuria and perinatal lethality in mice lacking NEPH1, a novel protein with homology to NEPHRIN. Mol Cell Biol 21:4829–4836
Council NR (1996) Guide for the Care and Use of Laboratory Animals. National Academy Press, Washington, DC
Tinsley FC, Taicher GZ, Heiman ML (2004) Evaluation of a quantitative magnetic resonance method for mouse whole body composition analysis. Obes Res 12:150–160
Silver J, Keerikatte V (1989) Novel use of polymerase chain reaction to amplify cellular DNA adjacent to an integrated provirus. J Virol 63:1924–1928
Benigni A, Remuzzi G (1996) Glomerular protein trafficking and progression of renal disease to terminal uremia. Semin Nephrol 16:151–159
Nagata M, Tomari S, Kanemoto K, Usui J, Lemley KV (2003) Podocytes, parietal cells, and glomerular pathology: the role of cell cycle proteins. Pediatr Nephrol 18:3–8
Ghiggeri GM, Carraro M, Vincenti F (2004) Recurrent focal glomerulosclerosis in the era of genetics of podocyte proteins: theory and therapy. Nephrol Dial Transplant 19:1036–1040
D’Agati VD, Fogo AB, Bruijn JA, Jennette JC (2004) Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis 43:368–382
Stan RV, Tkachenko E, Niesman IR (2004) PV1 is a key structural component for the formation of the stomatal and fenestral diaphragms. Mol Biol Cell 15:3615–3630
Stan RV, Ghitescu L, Jacobson BS, Palade GE (1999) Isolation, cloning, and localization of rat PV-1, a novel endothelial caveolar protein. J Cell Biol 145:1189–1198
Kriz W, Elger M, Mundel P, Lemley KV (1995) Structure-stabilizing forces in the glomerular tuft. J Am Soc Nephrol 5:1731–1739
Satchell SC, Anderson KL, Mathieson PW (2004) Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties. J Am Soc Nephrol 15:566–574
Eremina V, Quaggin SE (2004) The role of VEGF-A in glomerular development and function. Curr Opin Nephrol Hypertens 13:9–15
Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE (2003) Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111:707–716
Roberts WG, Palade GE (1995) Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 108:2369–2379
Tryggvason K (1999) Unraveling the mechanisms of glomerular ultrafiltration: nephrin, a key component of the slit diaphragm. J Am Soc Nephrol 10:2440–2445
Boute N, Gribouval O, Roselli S, Benessy F, Lee H, Fuchshuber A, Dahan K, Gubler MC, Niaudet P, Antignac C (2000) NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 24:349–354
Kaplan JM, Kim SH, North KN, Rennke H, Correia LA, Tong HQ, Mathis BJ, Rodriguez-Perez JC, Allen PG, Beggs AH, Pollak MR (2000) Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet 24:251–256
Yao J, Le TC, Kos CH, Henderson JM, Allen PG, Denker BM, Pollak MR (2004) Alpha-actinin-4-mediated FSGS: an inherited kidney disease caused by an aggregated and rapidly degraded cytoskeletal protein. PLoS Biol 2:E167
Acknowledgements
We thank Elizabeth Wilson for immunohistochemistry and Kathy Troughton for electron microscopy support, and Carol Jones for obtaining the urinalysis data.
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was presented in part at the IPNA Seventh Symposium on Growth and Development in Children with Chronic Kidney Disease: The Molecular Basis of Skeletal Growth, 1–3 April 2004, Heidelberg, Germany
Rights and permissions
About this article
Cite this article
Powell, D.R., Desai, U., Sparks, M.J. et al. Rapid development of glomerular injury and renal failure in mice lacking p53R2. Pediatr Nephrol 20, 432–440 (2005). https://doi.org/10.1007/s00467-004-1696-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-004-1696-5